Orally Disintegrating Tablet Excipient by Type (Binders, Glidents, Diluents, Disintegrants, Others), by Application (Anti-Psychotics Drug, Anti-Epileptics Drug, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
The Orally Disintegrating Tablet (ODT) excipient market, valued at $16.2 billion in 2025, is poised for robust expansion. This growth, projected at a Compound Annual Growth Rate (CAGR) of 8.6%, is propelled by the increasing adoption of patient-centric drug delivery solutions. Key growth drivers include the escalating demand for easily ingestible medications among the aging population, the rising incidence of chronic conditions requiring consistent treatment, and the pharmaceutical sector's emphasis on enhancing patient adherence. Leading manufacturers such as BASF, JRS Pharma, and Roquette are actively innovating to refine excipient performance, resulting in advanced ODT formulations offering superior taste masking, accelerated disintegration, and improved stability. Market segmentation by excipient type, including superdisintegrants, binders, and fillers, will reveal diverse growth patterns contingent on specific applications and performance attributes. Furthermore, regulatory approvals and the expanding therapeutic applications of ODTs are significant contributors to market development.
Orally Disintegrating Tablet Excipient Market Size (In Billion)
30.0B
20.0B
10.0B
0
16.20 B
2025
17.59 B
2026
19.11 B
2027
20.75 B
2028
22.53 B
2029
24.47 B
2030
26.58 B
2031
The forecast period (2025-2033) indicates a sustained upward trend for the ODT excipient market. Market dynamics will be shaped by evolving competitive landscapes, technological innovations in excipient production, and a growing emphasis on sustainable and cost-effective solutions. Regional healthcare infrastructure and regulatory environments will also play a crucial role in market segmentation and regional growth differentials.
Orally Disintegrating Tablet Excipient Company Market Share
Loading chart...
Orally Disintegrating Tablet Excipient Trends
The orally disintegrating tablet (ODT) excipient market is experiencing robust growth, driven by the increasing demand for convenient and patient-friendly drug delivery systems. The market, valued at several billion units in 2025, is projected to witness significant expansion during the forecast period (2025-2033), exceeding tens of billions of units. This growth is fueled by several factors, including the rising geriatric population, the increasing prevalence of chronic diseases requiring frequent medication, and the growing preference for easy-to-administer dosage forms, especially among children and elderly patients. The market is witnessing innovation in excipient types, with a focus on improved taste-masking, faster disintegration times, and enhanced stability. This trend is attracting significant investment from major players, leading to the development of novel excipients and formulations. Furthermore, regulatory approvals for innovative ODT products are adding to the market momentum. The historical period (2019-2024) showcased a steady increase in market size, setting the stage for the projected exponential growth. Key market insights suggest a shift towards natural and biocompatible excipients, driven by increasing consumer awareness and regulatory pressures for safer pharmaceutical products. Competition is intensifying among major players, prompting strategic collaborations, mergers, and acquisitions to expand market share and product portfolios. The market is segmented based on excipient type (e.g., sweeteners, binders, disintegrants), application (e.g., cardiovascular, oncology, pediatrics), and geography. Understanding these segment-specific dynamics is crucial for effective market penetration strategies. Overall, the ODT excipient market presents a lucrative opportunity for companies to capitalize on the growing demand for convenient and patient-centric drug delivery solutions.
Driving Forces: What's Propelling the Orally Disintegrating Tablet Excipient Market?
Several key factors are propelling the growth of the orally disintegrating tablet (ODT) excipient market. The aging global population represents a significant driver, as older adults often experience difficulties swallowing traditional tablets and capsules. ODTs offer a convenient and easy-to-administer alternative, enhancing medication adherence and improving patient outcomes. Furthermore, the increasing prevalence of chronic diseases like diabetes, hypertension, and cardiovascular diseases, which often require daily medication, fuels the demand for convenient dosage forms. The growing acceptance of ODTs among pediatric patients, where palatability is crucial, further contributes to market growth. Technological advancements in excipient technology have also led to the development of improved formulations with faster disintegration times, better taste-masking properties, and enhanced stability. This constant innovation attracts pharmaceutical companies to incorporate ODTs into their product pipelines. The increasing focus on patient-centric drug delivery systems within the pharmaceutical industry actively encourages the adoption of ODTs, boosting the demand for specialized excipients. Finally, supportive regulatory frameworks in several countries, streamlining the approval process for novel ODT formulations, further accelerate market growth.
Challenges and Restraints in Orally Disintegrating Tablet Excipient Market
Despite the promising growth prospects, the ODT excipient market faces several challenges. The complex formulation process of ODTs, requiring precise control over various parameters to achieve desired disintegration and dissolution profiles, presents a significant hurdle for manufacturers. Maintaining the stability of sensitive drug substances within the ODT formulation is also a critical concern, as moisture and temperature fluctuations can affect drug efficacy and shelf life. The high cost of specialized excipients compared to traditional tablet excipients can limit market penetration, especially in price-sensitive regions. Furthermore, the need for stringent quality control measures throughout the manufacturing process adds to the overall cost, impacting profitability. Regulatory hurdles and varying regulatory guidelines across different countries can complicate product approvals and market entry strategies. The potential for inconsistent disintegration times due to variations in manufacturing and environmental conditions poses a challenge to ensuring product quality and patient safety. Finally, intense competition from established players and the entry of new players with innovative formulations create a dynamic market landscape requiring continuous innovation and adaptation.
Key Region or Country & Segment to Dominate the Market
North America: This region is expected to dominate the market due to high healthcare expenditure, a large geriatric population, and a strong pharmaceutical industry. The established regulatory framework and the presence of major pharmaceutical companies actively involved in ODT development further contribute to the region's leading position. Technological advancements and the focus on patient-centric drug delivery solutions also play a vital role in fueling market growth.
Europe: This region holds a significant share, driven by rising healthcare expenditure, an aging population, and a robust regulatory framework. Stringent regulations may necessitate higher quality excipients but also contribute to improved patient outcomes and trust. Research and development activities within the European pharmaceutical sector continuously propel the adoption of advanced ODT formulations.
Asia Pacific: This region displays significant growth potential due to increasing disposable income, rising healthcare awareness, and a growing geriatric population. However, variations in regulatory standards across different countries and the availability of affordable generic drugs present some challenges.
Segments: The segment of sweeteners for taste-masking and disintegrants for fast disintegration are expected to show robust growth, reflecting the crucial roles they play in achieving the desirable properties of ODTs. The pediatric and geriatric segments will also experience substantial growth due to the unique advantages ODTs offer these patient populations.
The overall market is characterized by the increasing demand for specialized excipients that deliver superior taste-masking, rapid disintegration, and enhanced stability. This necessitates substantial investment in research and development of advanced excipients tailored for specific applications and patient populations. The competitive landscape features several leading players with a global presence, actively engaging in strategic acquisitions, collaborations, and innovations. This dynamic environment fosters continuous advancement in the technology and applications of ODT excipients.
Growth Catalysts in Orally Disintegrating Tablet Excipient Industry
The ODT excipient market is propelled by several key growth catalysts. Increasing patient preference for convenient medication administration methods is paramount. This is amplified by the growing elderly population worldwide, who often struggle with traditional oral dosage forms. Technological innovations continuously improve ODT formulations, offering faster disintegration, enhanced stability, and better taste-masking properties. These advancements attract both pharmaceutical companies and patients alike, contributing to market growth. Regulatory support for ODTs, evident in many countries' streamlined approval processes, encourages development and adoption of innovative ODT formulations.
Leading Players in the Orally Disintegrating Tablet Excipient Market
BASF
JRS Pharma
Roquette
ABF Ingredients
DFE Pharma
Evonik
Merck KGaA
Ashland
Meggle Pharma
Shin-Etsu
Fuji Chemical Industries
McePharma (Vivesa holding)
Cargill Incorporated
Daicel Corporation
Anhui Sunhere Pharmaceutical
Significant Developments in Orally Disintegrating Tablet Excipient Sector
2020: Introduction of a novel super disintegrant by DFE Pharma.
2021: Strategic partnership between BASF and a major pharmaceutical company to develop new ODT excipients.
2022: Acquisition of a specialized excipient manufacturer by Roquette.
2023: Launch of a new line of natural ODT excipients by Cargill.
2024: Approval of a novel ODT formulation using a new excipient from Evonik.
The orally disintegrating tablet (ODT) excipient market presents an impressive opportunity for significant growth. The market's expansion is fueled by a confluence of factors, including an aging global population, technological advancements leading to improved ODT formulations, and supportive regulatory frameworks. The market is segmented by excipient type, application, and geography, exhibiting unique growth dynamics within each segment. Leading players are actively shaping the market landscape through strategic collaborations, acquisitions, and continuous innovation. The projected growth trajectory signifies a promising outlook for the industry over the forecast period.
Table 91: Rest of Asia Pacific Orally Disintegrating Tablet Excipient Revenue (billion) Forecast, by Application 2020 & 2033
Table 92: Rest of Asia Pacific Orally Disintegrating Tablet Excipient Volume (K) Forecast, by Application 2020 & 2033
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders
Secondary Research
Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Orally Disintegrating Tablet Excipient?
The projected CAGR is approximately 8.6%.
2. Which companies are prominent players in the Orally Disintegrating Tablet Excipient?
Key companies in the market include BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, McePharma (Vivesa holding), Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical.
3. What are the main segments of the Orally Disintegrating Tablet Excipient?
The market segments include Type, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 16.2 billion as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3480.00, USD 5220.00, and USD 6960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Orally Disintegrating Tablet Excipient," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Orally Disintegrating Tablet Excipient report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Orally Disintegrating Tablet Excipient?
To stay informed about further developments, trends, and reports in the Orally Disintegrating Tablet Excipient, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Orally Disintegrating Tablet Excipient